Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial
Authors
Keywords
-
Journal
BLOOD
Volume 118, Issue 14, Pages 3824-3831
Publisher
American Society of Hematology
Online
2011-08-10
DOI
10.1182/blood-2011-05-352039
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
- (2011) Lewis R. Silverman et al. CANCER
- DNMT3B gene amplification predicts resistance to DNA demethylating drugs
- (2011) Laia Simó-Riudalbas et al. GENES CHROMOSOMES & CANCER
- Transcription intermediary factor 1γ is a tumor suppressor in mouse and human chronic myelomonocytic leukemia
- (2011) Romain Aucagne et al. JOURNAL OF CLINICAL INVESTIGATION
- Hypomethylating Agents and Other Novel Strategies in Myelodysplastic Syndromes
- (2011) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance
- (2011) V Grossmann et al. LEUKEMIA
- Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms
- (2011) O Abdel-Wahab et al. LEUKEMIA
- Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia
- (2010) J. Bies et al. BLOOD
- ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
- (2010) Véronique Gelsi-Boyer et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
- (2010) Bart L. Scott et al. BRITISH JOURNAL OF HAEMATOLOGY
- Activity of azacitidine in chronic myelomonocytic leukemia
- (2010) Rubens Costa et al. CANCER
- Chromatin Remodeling Is Required for Gene Reactivation after Decitabine-Mediated DNA Hypomethylation
- (2010) J. Si et al. CANCER RESEARCH
- Cytogenetic risk stratification in chronic myelomonocytic leukemia
- (2010) E. Such et al. HAEMATOLOGICA
- Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1
- (2010) Alexander Kohlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration
- (2010) O Abdel-Wahab et al. LEUKEMIA
- Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes
- (2010) M Y Follo et al. LEUKEMIA
- Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia
- (2009) N. Droin et al. BLOOD
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
- (2009) T. E. Fandy et al. BLOOD
- Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
- (2009) F. H. Grand et al. BLOOD
- TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia
- (2009) O. Kosmider et al. HAEMATOLOGICA
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation
- (2009) M-C Kuo et al. LEUKEMIA
- Increased c-Jun Expression and Reduced GATA2 Expression Promote Aberrant Monocytic Differentiation Induced by Activating PTPN11 Mutants
- (2009) Z. Yang et al. MOLECULAR AND CELLULAR BIOLOGY
- Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines
- (2008) T. Qin et al. BLOOD
- Outcome of allo-SCT for chronic myelomonocytic leukemia
- (2008) S Ocheni et al. BONE MARROW TRANSPLANTATION
- Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
- (2007) P.W. Wijermans et al. LEUKEMIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More